Inflammatory Disease News and Research

RSS

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

New study: Asthma may have relationship with airway microbiota composition

Asthma may have a surprising relationship with the composition of the species of bacteria that inhabit bronchial airways, a finding that could suggest new treatment or even potential cures for the common inflammatory disease, according to a new UCSF-led study.

18 Feb 2011

Study finds link between poor sleep quality and functional disability in RA patients

A study in the Feb. 15 issue of the Journal of Clinical Sleep Medicine found that poor sleep quality correlated with higher levels of depressive symptoms, greater pain severity, increased fatigue, and greater functional disability in patients with Rheumatoid Arthritis.

15 Feb 2011

Free, confidential home-kit testing for sexually transmitted infections effective with young people

Infectious disease experts at Johns Hopkins say new research clearly shows that screening teens and young adults for sexually transmitted infections may best be achieved by making free, confidential home-kit testing available over the Internet. From a public health standpoint, the project is a clear winner, the experts say.

14 Feb 2011

First evidence of human DNA fragment in bacterial genome

If a human cell and a bacterial cell met at a speed-dating event, they would never be expected to exchange phone numbers, much less genetic material. In more scientific terms, a direct transfer of DNA has never been recorded from humans to bacteria.

14 Feb 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

ACR releases two new provisional definitions of rheumatoid arthritis remission

The American College of Rheumatology today announced the release of two new provisional definitions of rheumatoid arthritis remission, which are to be applied to future RA clinical trials.

4 Feb 2011

CVT more common than previously thought, disproportionally affects pregnant women

A rare and often underreported form of stroke that involves veins instead of arteries is more common than previously thought, according to the American Heart Association's first scientific statement on diagnosing and managing cerebral venous thrombosis (CVT).

4 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Researchers to develop new diagnostics platform for early detection of lung cancer

The earlier cancers can be detected, the better the chances of a cure. Researchers are now working to develop a new diagnostics platform with which the illness can be diagnosed in its early stages, even during a visit to the general practitioner: protein biomarkers in exhaled air divulge the presence of pathological cells in the lung.

3 Feb 2011

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.

21 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Maintaining periodontal health may contribute to a healthy respiratory system, according to research published in the Journal of Periodontology. A new study suggests that periodontal disease may increase the risk for respiratory infections, such as chronic obstructive pulmonary disease (COPD) and pneumonia.

19 Jan 2011

Inflammation “master switch” found: Study

According to the latest medical discovery a protein that acts as a “master switch” has been found to determine whether certain white blood cells will boost or dampen inflammation. This may open new avenues in rheumatoid arthritis research. Rheumatoid arthritis or RA is an inflammatory disease that causes severe progressive crippling of the joints.

17 Jan 2011

Enlight Biosciences forms new oral drug delivery technology company

Entrega, Inc., a new company developing oral drug delivery technologies, today announced its formation by Enlight Biosciences, a Boston-based company established in partnership with a group of leading global pharmaceutical companies.

10 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Study compares treatment cost of PID hospitalizations, ER care for teen girls

Hospitalizing teen girls with pelvic inflammatory disease costs six times as much as treating them in the emergency room, and up to 12 times more than treating them in an outpatient clinic, according to a small study conducted at the Johns Hopkins Children's Center.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Inflammatory Disease News and Research

Why are Chlamydia and HPV major public health problems?

New study: Asthma may have relationship with airway microbiota composition

Study finds link between poor sleep quality and functional disability in RA patients

Free, confidential home-kit testing for sexually transmitted infections effective with young people

First evidence of human DNA fragment in bacterial genome

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

ACR releases two new provisional definitions of rheumatoid arthritis remission

CVT more common than previously thought, disproportionally affects pregnant women

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Researchers to develop new diagnostics platform for early detection of lung cancer

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Inflammation “master switch” found: Study

Enlight Biosciences forms new oral drug delivery technology company

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Study compares treatment cost of PID hospitalizations, ER care for teen girls

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News